DOCSLIB.ORG

GASTROENTEROLÓGICA LATINOAMERICANA Vol 51 Nº2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
GASTROENTEROLÓGICA LATINOAMERICANA Vol 51 Nº2 Vol 51 Nº2 año 2021 GASTROENTEROLÓGICA LATINOAMERICANA ISSN: 2469-1119 Bajo riesgo de infección por COVID-19 en un centro de endoscopía SECCIÓN EVIDENCIAS 181 gastrointestinal ambulatoria en la Argentina José Tawil, Josie Libertucci, Ana Adet Caldelari, Irene Banchero, Sandra Canseco, Sesgo de inmortalidad en estudios observacionales Ricardo Figueredo, Maria Garcia, Cristina Machado, Vanesa Del Arbol, Christian 125 Diego Pérez de Arenaza Sánchez, Elena F Verdu, Cecilio Cerisoli, Luis Caro Los criterios de Rosemont en ultrasonografía endoscópica: ¿son REVISIONES 189 predictores de insuciencia pancreática exocrina? Marianela Arramón, Agustina Redondo, Pablo Cura, Fernando Baldoni, Ana Brizio, Novedades acerca de los trastornos motores del esófago tras Cecilia Loudet, Francisco Tufareo Ventura 131 la reciente clasicación de Chicago 4.0 Claudia Córdoba, Agustina Rodil, Daniel Cisternas Comparación entre los criterios diagnósticos del síndrome de intestino 196 irritable en una población latinoamericana. Estudio descriptivo de un Dispepsia funcional y gastroparesia: ¿dos entidades hospital de atención terciaria 143 superpuestas? De la siopatología a la terapéutica Tatiana Noemí Uehara, Harumi Hashimoto, Federico Bazán, Adriana Tévez, Gladys María Mercedes Manresa, Paula Cecilia Carboné, Guillermina Diez Bravo, Sara Schaab, Juan Antonio Sordá IMÁGENES DEL NÚMERO CASOS CLÍNICOS Complicación posretrasplante hepático Un caso raro de púrpura trombocitopénica trombótica causada por 163 Mariana Bello, Nebil Larrañaga, German Espil, Shigeru Kozima, Fabiana Prado 203 pancreatitis aguda Emin Gemcioglu, Mehmet Kayaalp, Merve Caglayan, Ahmet Ceylan, Mehmet Sezgin Pepeler Hallazgo incidental postrauma abdominal 164 Diana Marcela Rodríguez De La Hoz, Margareth Mendoza Álvarez, María Adenocarcinoma duodenal en un paciente con dermatitis Eugenia Orozco, María De Vedia, Nicolás Roccatagliata, Ricardo Cobeñas, 207 herpetiforme. Reporte de un caso Nebil Larrañaga Martín Oricchio, Yéssica Pontet, Andrés Taullard, Carolina Olano Resección endoscópica bajo visión coledocoscópica de pólipo biliar. MANUSCRITOS ORIGINALES 213 Reporte de un caso Aníbal Soler, Gonzalo Palmili, Eduardo Cassone, Aníbal Silva Perl clínico de pacientes pediátricos con diagnóstico de 165 hepatitis autoinmune en un centro de alta complejidad del Hepatitis aguda por virus E con características de autoinmunidad. suroccidente colombiano 217 Reporte de un caso Carolina Aristizábal-Henao, Laura Torres-Canchala, Eliana Manzi, Verónica María Laura Garrido, María Laura Reyes Toso, Sebastián Raffa, Valeria Inés Descalzi Botero-Osorio Paniculitis en pancreatitis aguda. Reporte de un caso y revisión de la Prevalencia de mucosa gástrica heterotópica cervical y su 223 literatura 173 relación con síntomas de reujo gastroesofágico. Estudio Rómulo Vargas, Alan Ovalle Hernández, Daniela Cáceres Escobar, Oscar Lucero Pantoja observacional Natalia Marina Zeytuntsian, José Tawil, Ana Adet Caldelari, Álvaro Falzone, Síndrome de Plummer-Vinson en un paciente con enfermedad celíaca. Patricio Sheridan, Gustavo Bello, Christian Sánchez, Luis Caro, Cecilio Cerisoli 228 Reporte de un caso Oscar Bedini, Ariel Naves, Patricia San Miguel, José Brunetti Órgano ocial Sociedad de Gastroenterología del Uruguay ACTA GASTROENTEROL LATINOAM - JUNIO 2021;VOL 51:Nº 2 COMITÉ EDITORIAL EDITOR EN JEFE Jorge A. Olmos Hospital de Clínicas José de San Martín, Universidad de Buenos Aires. Programa de Efectividad Clínica. Universidad de Buenos Aires, CABA EDITORES ASOCIADOS Julieta Argüero Hospital Italiano de Buenos Aires. María Marta Piskorz Juan Pablo Stefanolo Maestría en Hospital de Clínicas Hospital de Investigación José de San Martín, Gastroenterología Clínica. Instituto Universidad de Buenos Dr. Carlos Bonorino Universitario Aires. Programa de Udaondo. Programa Hospital Italiano Efectividad Clínica. de Efectividad Clínica. de Buenos Aires, Universidad de Buenos Universidad de Buenos CABA Aires, CABA Aires, CABA Los integrantes del Comité Editorial acreditan formación en Edición y Corrección de Publicaciones Científicas. Universidad de Valencia, España Para la evaluación y preparación de los manuscritos, se siguen los requerimientos del Committee on Publication Ethics (COPE) disponibles en https://publicationethics.org/resources/guidelines-new/principles-transparency-and-best-practice-scholarly-publishing. COORDINADORES DE SECCIONES SECCIÓN EVIDENCIAS SECCIÓN PASE DE GUARDIA REVISOR IMÁGENES DEL NÚMERO Coordinador: Coordinadora: Rodolfo Pizarro Cecilia Carraro Manuel Alejandro Mahler Jefe de Cardiología Hospital de del Hospital Italiano de Gastroenterología Servicio de Gastroenterología Buenos Aires. Master en Dr. Carlos Bonorino Hospital Italiano de Buenos Aires, Efectividad Clínica, CABA Udaondo, CABA CABA SECRETARIA SEGUINOS EN NUESTRAS REDES SOCIALES Tamara Alvarez Worobey PRODUCCIÓN Y EDICIÓN /actagastro Raúl Groizard DISEÑO Y ARMADO DIGITAL Alejandro Javier Sfich /ACTA_Gastro CORRECTORES Diana Evelin Person María Nochteff Avendaño /actagastro PUBLICIDAD Establecer contacto con: Secretaría Revista Acta: [email protected] o Sociedad Argentina de Gastroenterología: [email protected] Tel.: 4816-9396/9391 1 A 2 copy 12/4/13 00:57 PM Página 1 ACTA GASTROENTEROL LATINOAM - JUNIO 2021;VOL 51:Nº 2 ACTA GASTROENTEROL LATINOAM - DICIEMBRE 2013;VOL 43:Nº4 Órgano oficial Sociedad REVISORES NACIONALES Argentina de Gastroenterología Ana Adet Ramiro González Sueyro Alejandro Rey Valentina Araya Verónica Gorodner Ana Rocca Fernando Barreyro Ubaldo Gualdrini Andrés Ruf COMISIÓN DIRECTIVA COMISIÓN DIRECTIVA Sandra Basso Silvia Gutiérrez Judith Cohen Sabban SAGE - PERÍODO 2021 SGU - PERÍODO 2021-2022 Maricel Bellicoso Mauricio Guzmán José María Sanguinetti EDITOR EN JEFE COMITÉ CONSULTOR COMISIÓN DIRECTIVA COMISIÓN DIRECTIVA SAGE - PERÍODO 2013 SGU - BIENIO 2013-2015 Axel Beskow Hui Jer Hwang Fran Schlottmann José Luis Fernández FernandoPRESIDENTE Arroyo (Ecuador) PRESIDENTEPRESIDENTE PRESIDENTE Claudia Bestani Nadia Kujta Alberto Seehaus Alfredo García Eduardo Gutierrez Galiana COMITÉ EDITORIAL LeónFabio Barúa Nachman (Perú) Virginia López Román Bigliardi Matías Lafage Edgardo Smecuol 1er VICEPRESIDENTE Julio C. Bai VICEPRESIDENTE Henry Cohen (Uruguay) ER Asadur Tchekmedyian Jorge Bosch Oscar Laudanno Luis Soifer Rodolfo E. Corti Luis M. Bustos1 VICEPRESIDENTE Fernández 2do. VICEPRESIDENTE Maximiliano Bun Mariano Loureiro Silvia Susana Soler JuanVICEPRESIDENTE C. Chiocca (Argentina) Ximena Rodríguez Juan Andrés De Paula SECRETARIO María Antonieta Pessolano Alfredo Currás Fernando Cairo Carlos Miguel Lumi Eduardo Sosa Adrián Gadano Eran Goldin (Israel) Sergio Huernos SECRETARIA 2DO VICEPRESIDENTE Rubén Terg Laura Quintana Federico Cassella Manuel Mahler Juan Spina Roberto Groszmann (EE.UU.) PROSECRETARIAAlberto Sanguinetti SECRETARIA Rosana Argento TESORERO Juan Pablo Campana Mercedes Manresa Leandro Steinberg SECRETARIA Vicente Gutiérrez (Argentina) Claudio Iglesias María C. Cañero Velasco Eduardo Mauriño Hugo Tanno Dolores Matoso TESORERASECRETARIA Mariela García Muñoz SECRETARIA DE ACTAS Alejandro Jmelnitzky (Argentina) Judith DoweckYéssica Pontet Alicia Pérez Medeiros Marcela Carballido Ezequiel Matías Mauro María del Carmen Toca CORRECTOR DavidPROSECRETARIA Kravetz (EE.UU.) PROTESORERO VOCALES Cecilia Carraro Dolores Matoso Lucio Uranga TESORERO Hernán Sassi Josefina Etchevers Ubaldo Gualdrini Rosa Cruells Mariano Cartier Lucas McCormack Carlos Vaccaro Oscar Laudanno (Argentina) Sergio Vázquez Patricia Gaggero VOCALES TITULARES Cecilio Cerisoli Guillermo Mendez María Inés Vaccaro IMPRESIÓN Roberto Santos Lucero (Argentina) Carolina Fischer SUPLENTE PREFERENCIALES TESORERA SECRETARIA DE ACTASArtigas Escudero Karina Collia Daniela Milito Amanda Varela www.latingrafica.com.ar Carolina Bolino Pedro Llorens (Chile) Martha Ribeiro Luis Colombato Alejandro Moreira Mariano Villarroel Maricel Bellicoso Daniel PeraltaInés Trucco PUBLICIDAD Fernando Magnanini (Argentina) PROGRAMACIÓN NACIONAL Mónica Contreras María Laura Moreno Mariano Volpacchio Establecer contacto con VOCALES SUPLENTESVOCALES Álvaro Fiorini Víctor Pérez (Argentina) Javier Valentini Florencia Costa Fabio Nachman Marta Wagener [email protected] PROTESORERO Ana Brito PROGRAMACIÓN INTERNACIONAL Ma. Ines Delli Quadri Horacio Gutiérrez Galiana Andrea Curia Adrián Narvaez Daniel Wainstein Tel. 4864-8716 Alejandro Pulpeiro (Argentina) Martín Toro Raquel GonzálezMarie Howe COMISIÓN FISCAL Cecilia Curvale Alejandro Nieponice Florencia Yamasato Humberto Reyes (Chile) PRESIDENTE CONSULTORSUPLENTES EX–PRESIDENTE PREFERENCIALESJavier Barreiro Jorge Daruich Juan Manuel O’Connor David Zagalsky EduardoVOCALES Schiffrin TITULARES (Argentina) Claudio Bilder Adriana Raggio INTEGRANTES Juan Andrés De Paula Juan Ignacio Olmos Natalia Zamora Claudia Bestani Hugo Tanno (Argentina) CONSEJO ASESORViviana DE SAGE NachmannCarlos Batalla Judith Doweck Agostina Pascual Russo Hugo Zandalazini María Eugenia Oregui Claudio BilderLaura Reyes Guido Annuiti Jorge Valenzuela (Chile) Lucila Facio Analía Verónica Pasqua Cecilia Zubiri Josefina Sobrero Horacio Vázquez SUPLENTES Guido Villa Gómez (Bolivia) Roberto MazurePROGRAMACIÓN CeciliaNACIONAL Torres José L. Fernández Silvina Paz Luis Viola José Figuera Susana Kohen Estanislao Gómez Florencia Pollarsky RobertoVOCALES Zeilicoff SUPLENTES (Argentina) Ricardo Mastai Ethel Szafer Andrea González Margarita Ramonet Gustavo Fabian Benito PROGRAMACIÓN Juan Manuel Marini INTERNACIONAL María Lucila Petruzzi Carolina Olano REVISORES INTERNACIONALES
Load more

Recommended publications
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Durham E-Theses
    Durham E-Theses Elemental Fluorine for the Greener Synthesis of Life-Science Building Blocks HARSANYI, ANTAL How to cite: HARSANYI, ANTAL (2016) Elemental Fluorine for the Greener Synthesis of Life-Science Building Blocks, Durham theses, Durham University. Available at Durham E-Theses Online: http://etheses.dur.ac.uk/11705/ Use policy The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for personal research or study, educational, or not-for-prot purposes provided that: • a full bibliographic reference is made to the original source • a link is made to the metadata record in Durham E-Theses • the full-text is not changed in any way The full-text must not be sold in any format or medium without the formal permission of the copyright holders. Please consult the full Durham E-Theses policy for further details. Academic Support Oce, Durham University, University Oce, Old Elvet, Durham DH1 3HP e-mail: [email protected] Tel: +44 0191 334 6107 http://etheses.dur.ac.uk 2 Durham University A thesis entitled Elemental Fluorine for the Greener Synthesis of Life-Science Building Blocks by Antal Harsanyi (College of St. Hild and St. Bede) A candidate for the degree of Doctor of Philosophy Department of Chemistry, Durham University 2016 Antal Harsanyi: Elemental fluorine for the greener synthesis of life-science building blocks Abstract Fluorinated organic compounds are increasingly important in many areas of our modern lives, especially in pharmaceutical and agrochemical applications where the incorporation of this element can have a major influence on biochemical properties.
    [Show full text]
  • Do We Need New Prokinetics to Reduce Enteral Feeding Intolerance During Critical Illness? Arthur Raymond Hubert Van Zanten
    van Zanten Critical Care (2016) 20:294 DOI 10.1186/s13054-016-1466-3 EDITORIAL Open Access Do we need new prokinetics to reduce enteral feeding intolerance during critical illness? Arthur Raymond Hubert van Zanten See related research by Chapman et al., http://ccforum.biomedcentral.com/articles/10.1186/s13054-016-1420-4 Abstract Gastrointestinal feeding intolerance and critical illness-associated gastric motility dysfunction are common. Although recent guidelines recommend not interrupting gastric feeding when gastric residual volume (GRV) is lower than 500 mL or to completely abandon measurement of GRV, it may seem that the relevance of prokinetics is reduced. In patients at risk for aspiration and in multimodal strategies to enhance feeding performance, however, use of prokinetics is still advocated. Metoclopramide and erythromycin are commonly used promotility agents, although with relevant side effects. Potential targets for new agents and early study results are addressed. Keywords: Promotility agents, Prokinetics, Feeding intolerance, Gastric emptying, Gastric residual volume, Metoclopramide, Erythromycin, Ghrelin Commentary daily for tolerance of EN and inappropriate cessation of A clear consensus definition on acute gastrointestinal in- EN should be avoided. Administration should be diverted jury during critical illness is lacking. Gastrointestinal lower in the gastrointestinal tract (post-pyloric feeding) in feeding intolerance (GFI) is usually defined by vomiting, patients at high risk for aspiration or in case of gastric EN abdominal distention, complaints of discomfort, high intolerance [4]. nasogastric tube output, high gastric residual volumes Now here a clinical dilemma may arise: The most (GRVs) measured at intervals, diarrhea, reduced passage likely routine to monitor GFI is to measure GRV.
    [Show full text]
  • A Motilin Agonist, on Gastric Emptying and Glucose Absorption In
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Springer - Publisher Connector Chapman et al. Critical Care (2016) 20:232 DOI 10.1186/s13054-016-1420-4 RESEARCH Open Access The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial Marianne J. Chapman1,2*, Adam M. Deane1,2, Stephanie L. O’Connor1,2, Nam Q. Nguyen3,4, Robert J. L. Fraser5, Duncan B. Richards6, Kimberley E. Hacquoil6, Lakshmi S. Vasist Johnson7, Matthew E. Barton7 and George E. Dukes7 Abstract Background: The promotility agents currently available to treat gastroparesis and feed intolerance in the critically ill are limited by adverse effects. The aim of this study was to assess the pharmacodynamic effects and pharmacokinetics of single doses of the novel gastric promotility agent motilin agonist camicinal (GSK962040) in critically ill feed- intolerant patients. Methods: A prospective, randomized, double-blind, parallel-group, placebo-controlled, study was performed in mechanically ventilated feed-intolerant patients [median age 55 (19–84), 73 % male, APACHE II score 18 (5–37) with a gastric residual volume ≥200 mL]. Gastric emptying and glucose absorption were measured both pre- and post- treatment after intragastric administration of 50 mg (n = 15) camicinal and placebo (n = 8) using the 13C-octanoic acid breath test (BTt1/2), acetaminophen concentrations, and 3-O-methyl glucose concentrations respectively. Results: Following 50 mg enteral camicinal, there was a trend to accelerated gastric emptying [adjusted geometric means: pre-treatment BTt1/2 117 minutes vs.
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]
  • G Protein‐Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology (2019) 176, S21–S141 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors Stephen PH Alexander1 , Arthur Christopoulos2 , Anthony P Davenport3 , Eamonn Kelly4, Alistair Mathie5 , John A Peters6 , Emma L Veale5 ,JaneFArmstrong7 , Elena Faccenda7 ,SimonDHarding7 ,AdamJPawson7 , Joanna L Sharman7 , Christopher Southan7 , Jamie A Davies7 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria 3052, Australia 3Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK 4School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 5Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 6Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 7Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website.
    [Show full text]
  • GPCR/G Protein
    Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com GPCR/G Protein G Protein Coupled Receptors (GPCRs) perceive many extracellular signals and transduce them to heterotrimeric G proteins, which further transduce these signals intracellular to appropriate downstream effectors and thereby play an important role in various signaling pathways. G proteins are specialized proteins with the ability to bind the nucleotides guanosine triphosphate (GTP) and guanosine diphosphate (GDP). In unstimulated cells, the state of G alpha is defined by its interaction with GDP, G beta-gamma, and a GPCR. Upon receptor stimulation by a ligand, G alpha dissociates from the receptor and G beta-gamma, and GTP is exchanged for the bound GDP, which leads to G alpha activation. G alpha then goes on to activate other molecules in the cell. These effects include activating the MAPK and PI3K pathways, as well as inhibition of the Na+/H+ exchanger in the plasma membrane, and the lowering of intracellular Ca2+ levels. Most human GPCRs can be grouped into five main families named; Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2, and Secretin, forming the GRAFS classification system. A series of studies showed that aberrant GPCR Signaling including those for GPCR-PCa, PSGR2, CaSR, GPR30, and GPR39 are associated with tumorigenesis or metastasis, thus interfering with these receptors and their downstream targets might provide an opportunity for the development of new strategies for cancer diagnosis, prevention and treatment. At present, modulators of GPCRs form a key area for the pharmaceutical industry, representing approximately 27% of all FDA-approved drugs. References: [1] Moreira IS. Biochim Biophys Acta. 2014 Jan;1840(1):16-33.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • A Motilin Agonist, on Gastric Emptying and Glucose
    Chapman et al. Critical Care (2016) 20:232 DOI 10.1186/s13054-016-1420-4 RESEARCH Open Access The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial Marianne J. Chapman1,2*, Adam M. Deane1,2, Stephanie L. O’Connor1,2, Nam Q. Nguyen3,4, Robert J. L. Fraser5, Duncan B. Richards6, Kimberley E. Hacquoil6, Lakshmi S. Vasist Johnson7, Matthew E. Barton7 and George E. Dukes7 Abstract Background: The promotility agents currently available to treat gastroparesis and feed intolerance in the critically ill are limited by adverse effects. The aim of this study was to assess the pharmacodynamic effects and pharmacokinetics of single doses of the novel gastric promotility agent motilin agonist camicinal (GSK962040) in critically ill feed- intolerant patients. Methods: A prospective, randomized, double-blind, parallel-group, placebo-controlled, study was performed in mechanically ventilated feed-intolerant patients [median age 55 (19–84), 73 % male, APACHE II score 18 (5–37) with a gastric residual volume ≥200 mL]. Gastric emptying and glucose absorption were measured both pre- and post- treatment after intragastric administration of 50 mg (n = 15) camicinal and placebo (n = 8) using the 13C-octanoic acid breath test (BTt1/2), acetaminophen concentrations, and 3-O-methyl glucose concentrations respectively. Results: Following 50 mg enteral camicinal, there was a trend to accelerated gastric emptying [adjusted geometric means: pre-treatment BTt1/2 117 minutes vs. post- treatment 76 minutes; 95 % confidence intervals (CI; 0.39, 1.08) and increased glucose absorption (AUC240min pre-treatment: 28.63 mmol.min/L vs.
    [Show full text]
  • Orally Active Compound Library (96-Well)
    • Bioactive Molecules • Building Blocks • Intermediates www.ChemScene.com Orally Active Compound Library (96-well) Product Details: Catalog Number: CS-L061 Formulation: A collection of 2244 orally active compounds supplied as pre-dissolved Solutions or Solid Container: 96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode Storage: -80°C Shipping: Blue ice Packaging: Inert gas Plate layout: CS-L061-1 1 2 3 4 5 6 7 8 9 10 11 12 a Empty Vonoprazan Mivebresib AZD0156 BAY-876 Tomivosertib PQR620 NPS-2143 R547 PAP-1 Delpazolid Empty Varenicline b Empty Varenicline (Hydrochlorid Varenicline A-205804 CI-1044 KW-8232 GSK583 Quiflapon MRK-016 Diroximel Empty e) (Tartrate) fumarate SHP099 c Empty A 922500 SHP099 (hydrochlorid Nevanimibe Pactimibe Pactimibe GNF-6231 MLi-2 KDM5-IN-1 PACMA 31 Empty e) hydrochloride (sulfate) Rilmenidine d Empty Cadazolid Treprostinil GSK3179106 Esaxerenone (hemifumarat Rilmenidine Fisogatinib BP-1-102 Avadomide Aprepitant Empty e) (phosphate) Cl-amidine AZD5153 (6- e Empty Maropitant Abscisic acid (hydrochlorid BGG463 WNK463 Ticagrelor Axitinib Hydroxy-2- CGS 15943 Pipamperone Empty e) naphthoic Setogepram Teglarinad f Empty Y-27632 GSK2193874 Lanabecestat CXD101 Ritlecitinib YL0919 PCC0208009 (sodium salt) (chloride) Futibatinib Empty TAK-659 g Empty NCB-0846 GS-444217 (hydrochlorid Navitoclax ABX464 Zibotentan Simurosertib (R)- CEP-40783 MK-8617 Empty e) Simurosertib Choline JNJ- h Empty CCT251236 (bitartrate) Sarcosine Brensocatib AS-605240 PF-06840003
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • Medicines in Development for Diabetes
    2014 MEDICINES IN DEVELOPMENT REPORT Diabetes PRESENTED BY AMERICA’S BIOPHARMACEUTICAL RESEARCH COMPANIES Biopharmaceutical Research Companies Are Developing 180 Medicines to Treat Diabetes and Related Conditions Nearly 26 million Americans are affected options for patients battling diabetes by diabetes—including 7 million people and diabetes-related conditions. who are unaware they have the disease. Medicines in Development One of the top 10 causes of death in the According to the Centers for Disease For Diabetes United States, diabetes has far-reaching Control and Prevention (CDC), death implications for patients and their fami- rates for people with diabetes fell sub- Application lies and our health care system. stantially—up to 40 percent—between Submitted 1997 and 2006. CDC links this decrease Phase III While healthy eating and exercise can to improved cardiovascular medical Phase II help prevent and manage type 2 diabe- treatment, better management of diabe- tes, medicines play a key role in helping tes, and some healthy lifestyle changes. Phase I reduce the risk of and treat the disease. For example, one medicine was found in Unfortunately, while the death rates due studies to lower the risk by 31 percent. to diabetes are declining, the rate of new cases has been rising. The number of 100 And in recent years, eight new classes of type 2 diabetes medicines have been ap- Americans diagnosed with diabetes has proved by the Food and Drug Administra- more than tripled since 1980, according tion (FDA), giving patients and health care to the CDC. Lifestyle choices can affect providers powerful new options to treat this increase.
    [Show full text]